ECSP23012981A - Inhibidores de sarm1 - Google Patents
Inhibidores de sarm1Info
- Publication number
- ECSP23012981A ECSP23012981A ECSENADI202312981A ECDI202312981A ECSP23012981A EC SP23012981 A ECSP23012981 A EC SP23012981A EC SENADI202312981 A ECSENADI202312981 A EC SENADI202312981A EC DI202312981 A ECDI202312981 A EC DI202312981A EC SP23012981 A ECSP23012981 A EC SP23012981A
- Authority
- EC
- Ecuador
- Prior art keywords
- sarm1
- sarm1 inhibitors
- inhibitors
- treating
- present disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069408P | 2020-08-24 | 2020-08-24 | |
| US202163142398P | 2021-01-27 | 2021-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23012981A true ECSP23012981A (es) | 2023-03-31 |
Family
ID=77775005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202312981A ECSP23012981A (es) | 2020-08-24 | 2023-02-23 | Inhibidores de sarm1 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12043613B2 (enExample) |
| EP (1) | EP4200293A1 (enExample) |
| JP (2) | JP7349046B2 (enExample) |
| KR (1) | KR20230057396A (enExample) |
| AU (2) | AU2021333558C1 (enExample) |
| BR (1) | BR112023002575A2 (enExample) |
| CA (1) | CA3189181A1 (enExample) |
| CL (1) | CL2023000525A1 (enExample) |
| CO (1) | CO2023001975A2 (enExample) |
| CR (1) | CR20230113A (enExample) |
| DO (1) | DOP2023000038A (enExample) |
| EC (1) | ECSP23012981A (enExample) |
| IL (1) | IL300586A (enExample) |
| MX (1) | MX2023002256A (enExample) |
| PE (1) | PE20230737A1 (enExample) |
| TW (2) | TW202334117A (enExample) |
| WO (1) | WO2022046606A1 (enExample) |
| ZA (1) | ZA202301801B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3897670A4 (en) | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| WO2022031736A1 (en) * | 2020-08-04 | 2022-02-10 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| EP4214197A1 (en) | 2020-09-16 | 2023-07-26 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| KR20240041987A (ko) | 2021-07-28 | 2024-04-01 | 누라 바이오, 인크. | Sarm1 억제제로서 치환된 피리딘 유도체 |
| US20240102018A1 (en) * | 2022-07-21 | 2024-03-28 | Amylyx Pharmaceuticals, Inc. | Oligonucleotide compositions and methods thereof |
| EP4634156A1 (en) * | 2022-12-15 | 2025-10-22 | Sironax Ltd | Sarm1 modulators, preparations, and uses thereof |
| CN121002009A (zh) | 2023-01-24 | 2025-11-21 | 达萨玛治疗公司 | 作为sarm1抑制剂的哒嗪类物 |
| TW202509019A (zh) * | 2023-04-27 | 2025-03-01 | 香港商維泰瑞隆（香港）生物科技有限公司 | Sarm1調節子、其製劑及用途 |
| CN119219603A (zh) * | 2023-06-28 | 2024-12-31 | 科辉智药(深圳)新药研究中心有限公司 | Sarm1酶活性抑制剂及其用途 |
| WO2025045746A1 (en) * | 2023-08-25 | 2025-03-06 | F. Hoffmann-La Roche Ag | Pyrazole derivatives as sarm1 inhibitors useful for the treatment of neurodegenerative disorders |
| WO2025049184A1 (en) | 2023-08-25 | 2025-03-06 | Eli Lilly And Company | (s)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4h-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate |
| WO2025076017A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Carbamates for use as sarm1 inhibitors |
| WO2025076088A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Lactams for use as sarm1 inhibitors |
| WO2025157895A1 (en) | 2024-01-25 | 2025-07-31 | UCB Biopharma SRL | Pyrrolidinone derivatives |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6436966B1 (en) | 1997-10-27 | 2002-08-20 | Takeda Chemical Ind., Ltd. | Adenosine A3 receptor antagonists |
| US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| EP1558607B1 (en) | 2002-10-30 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| EP1581222A2 (en) | 2003-01-02 | 2005-10-05 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr; |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| WO2005105780A2 (en) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| WO2006065946A1 (en) | 2004-12-16 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases |
| ES2396251T3 (es) | 2006-06-28 | 2013-02-20 | Aska Pharmaceutical Co., Ltd. | Derivado de piridilisoxazol |
| WO2008034600A1 (en) | 2006-09-21 | 2008-03-27 | Novartis Ag | Pyrrole derivatives useful for the treatment of cytokine-mediated diseases |
| US20100298286A1 (en) | 2007-12-20 | 2010-11-25 | Novartis Ag | Organic Compounds |
| PE20091523A1 (es) | 2007-12-20 | 2009-10-29 | Novartis Ag | Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k) |
| TW201004941A (en) | 2008-07-16 | 2010-02-01 | Wyeth Corp | Alpha7 nicotinic acetylcholine receptor inhibitors |
| US8785468B2 (en) | 2009-02-13 | 2014-07-22 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
| WO2012178022A2 (en) | 2011-06-24 | 2012-12-27 | University Of Massachusetts | Therapeutic applications targeting sarm1 |
| US9284310B2 (en) | 2012-11-03 | 2016-03-15 | Boehringer Ingelheim International Gmbh | Inhibitors of cytomegalovirus |
| EP2934536B1 (en) | 2012-12-19 | 2017-09-27 | Merck Sharp & Dohme Corp. | FACTOR IXa INHIBITORS |
| RU2570907C2 (ru) | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
| EP3076789A4 (en) | 2013-12-04 | 2017-11-22 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| EP4091622A1 (en) | 2016-08-16 | 2022-11-23 | Henry Ford Health System | Compositions for the treatment of chemotherapy-induced neuropathic pain |
| CN110545804A (zh) | 2016-09-24 | 2019-12-06 | 华盛顿大学 | Sarm1 nad酶活性抑制剂及其用途 |
| US20180251431A1 (en) | 2016-12-09 | 2018-09-06 | Vertex Pharmaceuticals Incorporated | 1,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levels |
| EP3558986A1 (de) * | 2016-12-22 | 2019-10-30 | Bayer CropScience Aktiengesellschaft | Substituierte 1,2,4-thiadiazolylpyrrolone und 1,2,4-thiadiazolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| CN110392680A (zh) | 2016-12-22 | 2019-10-29 | 拜耳作物科学股份公司 | 取代的唑基吡咯酮和唑基乙内酰脲及其盐及其作为除草活性物质的用途 |
| WO2019126733A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| ES3028093T3 (en) | 2018-06-07 | 2025-06-18 | Disarm Therapeutics Inc | Inhibitors of sarm1 |
| CN112839648B (zh) | 2018-06-07 | 2025-04-04 | 达萨玛治疗公司 | Sarm1抑制剂 |
| WO2019236890A1 (en) * | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| WO2020158762A1 (ja) | 2019-01-30 | 2020-08-06 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2020247701A2 (en) | 2019-06-06 | 2020-12-10 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| JP7319395B2 (ja) | 2019-06-14 | 2023-08-01 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
| CA3147858A1 (en) | 2019-07-22 | 2021-01-28 | Bayer Aktiengesellschaft | 5-amino substituted pyrazoles and triazoles as pest control agents |
| JP7534390B2 (ja) | 2019-09-12 | 2024-08-14 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
| CN114845709B (zh) | 2019-11-05 | 2024-10-01 | 德米拉公司 | 用于治疗炎性病症的mrgprx2拮抗剂 |
| BR112022013388A2 (pt) | 2020-01-07 | 2022-09-20 | Disarm Therapeutics Inc | Inibidores de sarm1 |
| JP7477642B2 (ja) | 2020-04-09 | 2024-05-01 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
| CN115916764B (zh) | 2020-04-09 | 2024-09-20 | 达萨玛治疗公司 | 作为sarm1抑制剂的吲唑衍生物 |
| WO2022031736A1 (en) | 2020-08-04 | 2022-02-10 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
-
2021
- 2021-08-20 TW TW111144632A patent/TW202334117A/zh unknown
- 2021-08-20 TW TW110130799A patent/TWI786777B/zh active
- 2021-08-23 CA CA3189181A patent/CA3189181A1/en active Pending
- 2021-08-23 JP JP2023513172A patent/JP7349046B2/ja active Active
- 2021-08-23 IL IL300586A patent/IL300586A/en unknown
- 2021-08-23 AU AU2021333558A patent/AU2021333558C1/en active Active
- 2021-08-23 PE PE2023000530A patent/PE20230737A1/es unknown
- 2021-08-23 CR CR20230113A patent/CR20230113A/es unknown
- 2021-08-23 WO PCT/US2021/047093 patent/WO2022046606A1/en not_active Ceased
- 2021-08-23 US US17/408,956 patent/US12043613B2/en active Active
- 2021-08-23 BR BR112023002575A patent/BR112023002575A2/pt unknown
- 2021-08-23 EP EP21770372.7A patent/EP4200293A1/en active Pending
- 2021-08-23 KR KR1020237009643A patent/KR20230057396A/ko active Pending
- 2021-08-23 MX MX2023002256A patent/MX2023002256A/es unknown
-
2023
- 2023-02-14 ZA ZA2023/01801A patent/ZA202301801B/en unknown
- 2023-02-22 CO CONC2023/0001975A patent/CO2023001975A2/es unknown
- 2023-02-22 CL CL2023000525A patent/CL2023000525A1/es unknown
- 2023-02-23 DO DO2023000038A patent/DOP2023000038A/es unknown
- 2023-02-23 EC ECSENADI202312981A patent/ECSP23012981A/es unknown
- 2023-09-08 JP JP2023145779A patent/JP7756130B2/ja active Active
-
2024
- 2024-05-21 AU AU2024203373A patent/AU2024203373A1/en active Pending
- 2024-06-19 US US18/747,889 patent/US20240376083A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202530197A (zh) | 2025-08-01 |
| JP7349046B2 (ja) | 2023-09-21 |
| KR20230057396A (ko) | 2023-04-28 |
| TWI786777B (zh) | 2022-12-11 |
| JP2023535236A (ja) | 2023-08-16 |
| MX2023002256A (es) | 2023-03-17 |
| CO2023001975A2 (es) | 2023-03-07 |
| AU2024203373A1 (en) | 2024-06-13 |
| TW202334117A (zh) | 2023-09-01 |
| US12043613B2 (en) | 2024-07-23 |
| WO2022046606A1 (en) | 2022-03-03 |
| AU2021333558A1 (en) | 2023-03-02 |
| ZA202301801B (en) | 2024-09-25 |
| IL300586A (en) | 2023-04-01 |
| PE20230737A1 (es) | 2023-05-03 |
| BR112023002575A2 (pt) | 2023-03-07 |
| JP7756130B2 (ja) | 2025-10-17 |
| JP2024016014A (ja) | 2024-02-06 |
| CR20230113A (es) | 2023-04-14 |
| AU2021333558B2 (en) | 2024-02-22 |
| US20240376083A1 (en) | 2024-11-14 |
| US20220056013A1 (en) | 2022-02-24 |
| DOP2023000038A (es) | 2023-03-15 |
| AU2021333558C1 (en) | 2024-06-20 |
| TW202214597A (zh) | 2022-04-16 |
| EP4200293A1 (en) | 2023-06-28 |
| CL2023000525A1 (es) | 2023-09-15 |
| CA3189181A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23012981A (es) | Inhibidores de sarm1 | |
| ECSP22053394A (es) | Inhibidores de sarm1 | |
| WO2020252229A3 (en) | Inhibitors of sarm1 | |
| BR112023020182A2 (pt) | Métodos para tratar câncer em um sujeito em necessidade do mesmo e para inibir ras em uma célula | |
| CO2024009571A2 (es) | Inhibidores de parp1 | |
| CA3140578C (en) | SARM1 INHIBITORS | |
| MX373965B (es) | Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae). | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| BR112024001180A2 (pt) | Composições e métodos para tratamento do melanoma | |
| PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| BR112022005895A2 (pt) | Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2 | |
| CL2021001246A1 (es) | Moduladores de expresión irf5. | |
| CO2024015614A2 (es) | Inhibidores de pi3kα | |
| WO2016154329A3 (en) | P38 map kinase inhibitors for treating friedreich's ataxia | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| EP4149943A4 (en) | VCP/p97 INHIBITOR FOR CANCER TREATMENT | |
| AR129088A1 (es) | INHIBIDORES DE PI3Ka | |
| AR117079A1 (es) | Moduladores de la expresión de foxp3 |